Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effisayil 2 dose-finding study of spesolimab for prevention of generalized pustular psoriasis flares
NL-OMON54870Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by Boehringer Ingelheim. Started Nov 2020; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NL-OMON54870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54870.